End of the Road for Delayed Hyperenhancement Cardiac Magnetic Resonance?⁎⁎Editorials published in JACC: Cardiovascular Imaging reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Imaging or the American College of Cardiology.  by Desai, Milind Y. & Flamm, Scott D.
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 2 , N O . 4 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c m g . 2 0 0 9 . 0 2 . 0 0 1E D I T O R I A L C O M M E N T
End of the Road for Delayed Hyperenhancement
Cardiac Magnetic Resonance?*
Milind Y. Desai, MD, Scott D. Flamm, MD
Cleveland, OhioDelayed hyperenhancement cardiac magnetic reso-
nance (DHE-CMR), although considered a robust
technique for the determination of myocardial via-
bility, nonetheless has perceived shortcomings as a
result of relatively long scan times, pacemaker/
defibrillator incompatibility, and, more recently,
concerns over development of nephrogenic systemic
fibrosis when using gadolinium in patients with
severe renal dysfunction (1). In this issue of iJACC,
Chang et al. (2) propose delayed contrast-enhanced
multidetector computed tomography (DCE-
MDCT) as an alternative to DHE-CMR, circum-
venting the latter’s shortcomings. Further, they
implement a modification to significantly reduce
the radiation dose, blunting one of the primary
concerns of MDCT scanning.
See page 412
This investigation extends a topic of great re-
search and clinical potential. Previously this group
has shown that retrospectively gated DCE-MDCT
is comparable to DHE-CMR in detection of large
myocardial scars in a porcine model (3). In the
current study, the investigators used a similar model
of acute myocardial infarction, albeit using electro-
cardiographic prospectively triggered DCE-
MDCT scans with an intention to reduce radiation
dose. Compared with a standard retrospectively
gated DCE-MDCT scan, the investigators showed
significant radiation dose savings, without a reduc-
tion in image quality, as measured by signal-to-
noise and contrast-to-noise ratios.
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the Heart and Vascular Institute and Imaging Institute, Cleveland
Clinic, Cleveland, Ohio.The potential for determining myocardial scar-
ring in combination with an MDCT scan for the
evaluation of coronary vessels/bypass grafts and left
ventricular function in a relatively rapid examina-
tion argues for a particularly compelling diagnostic
advantage. However, the use of MDCT in coronary
applications alone remains controversial along mul-
tiple lines of reasoning, but particularly as a result of
the high radiation burden (4–6). Indeed, routine
use of standard retrospectively gated MDCT scans
for coronary artery and scar assessment would
heighten these concerns, because it would necessi-
tate acquiring 2 separate scans and potentially
double the already significant radiation burden. In
the process of reducing this burden, the prospec-
tively triggered DCE-MDCT acquisition by
Chang et al. (2), with its attendant radiation dose
savings, presents an attractive alternative. In fact, if
the prospectively triggered technique is extended to
the submillimeter slice, coronary artery scan, “back
of the napkin” calculations suggest that this com-
bination (coronary artery and myocardial scar im-
aging) might be even lower in total radiation dose
than a typical retrospectively gated coronary artery
examination alone.
Nonetheless, before we jump onto the prospec-
tively triggered bandwagon, we need to consider the
potential shortcomings of prospectively triggered
scans. First, prospective scans, under most circum-
stances, do not allow for assessment of left ventric-
ular volumes or systolic function. Second, to avoid
step artifacts using typical 64-slice MDCT scan-
ners, a well-controlled and stable heart rate in the
50s to 60s is essential (although this concern may be
blunted with the advent of more extended range
configurations, such as the 8- to 16-cm z-axis
detector scanners). Frequently, adequate beta-
blockade is necessary for reducing heart rate. In the
clinical arena, such myocardial viability imaging is
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422ikely to be performed in patients with varying
egrees of heart failure, situations in which aggres-
ive control of heart rate may be more problematic.
hird, image quality in obese patients using pro-
pective scanning presents challenges for adequate
ube flux, and therefore image quality. Finally,
oncerns over the small but real potential for neph-
otoxicity with iodinated contrast agent remain.
To draw a distinction, let us examine some of the
otential strengths of CMR as a diagnostic tool in
he properly selected patient population. First and
oremost, it is rapidly gaining the position (if not
lready there) as the gold standard in myocardial
iability imaging (7). Further, CMR can accurately
nd reproducibly measure left ventricular function
nd volumes, as well as providing quantitative
nformation about valvular function, including mi-
ral regurgitant fraction (8). In addition, in experi-
nced centers, ischemia evaluation is performed
oncomitantly (9). Electrocardiographic prospec-
ively triggered DCE-MDCT currently is incapable
f providing this same breadth of data. Also, CMR
btains all of this information without concern for
adiation exposure. Another practical point to take
nto account concerns the patient population in
hich myocardial viability imaging is most impor-
ant, namely those undergoing surgical revascular-
zation. In most large centers, including our own,
ardiothoracic surgeons have yet to embrace
DCT coronary angiography, instead still relying
n traditional invasive angiography. And lastly,
HE-CMR has an established and growing wealth
f data establishing its safety and prognostic utility
10–12).
We also recognize additional continuing techni-
al challenges for DCE-MDCT in humans. In our
wn preliminary experience, performing DCE-
DCT using standard human doses of iodinated
ontrast (approximately 80 to 100 ml) yields images2:412–20. 298:317–23.o-noise ratio, and in general are of lesser quality
ompared with standard DHE-CMR. If we were to
xtrapolate the contrast dose used in the study by
hang et al. (2) for use in humans, a dose of 2 to 3
imes the current dose would be necessary. Such a
ose of iodinated contrast augers for heightened
aution in a population with potentially tenuous
enal function (i.e., patients with ischemic cardio-
yopathy and congestive heart failure). At present,
t is not at all clear what the optimal contrast dose
nd technique are for DCE-MDCT myocardial
nfarct and viability assessment. If indeed the con-
rast dose requirement is found to be higher, the
afety of such a strategy needs to be ascertained;
ingle-center and multi-center trials will also be
eeded to prove its reproducibility and utility.
Despite the breadth of concerns surrounding
he practicality and utility of and the radiation
ncurred with DCE-MDCT, the technique can-
ot be discounted. This technology remains early
n development, whereas the broad advances in
ardiac MDCT over the past few years—
mprovements in temporal resolution, prospective
riggering to reduce radiation dose, number of
etectors, dual-source and dual-energy scanners,
nd so on—have been dramatic. No doubt sim-
lar advances will occur in the arena of MDCT
yocardial viability determination. For now,
HE-CMR remains the clear frontrunner, al-
hough DCE-MDCT may soon become a rea-
onable alternative in patients not amenable to
MR. Further developments in DCE-MDCT
ortend budding challenges to DHE-CMR, and
ealthy, expanded debate.
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